JP6421128B2 - リアソータントインフルエンザａウイルス - Google Patents

リアソータントインフルエンザａウイルス Download PDF

Info

Publication number
JP6421128B2
JP6421128B2 JP2015544499A JP2015544499A JP6421128B2 JP 6421128 B2 JP6421128 B2 JP 6421128B2 JP 2015544499 A JP2015544499 A JP 2015544499A JP 2015544499 A JP2015544499 A JP 2015544499A JP 6421128 B2 JP6421128 B2 JP 6421128B2
Authority
JP
Japan
Prior art keywords
virus
segment
influenza
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015544499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501020A5 (https=
JP2016501020A (ja
Inventor
ピーター メイソン，
ピーター メイソン，
フィリップ ラルフ ドルミッチャー，
フィリップ ラルフ ドルミッチャー，
ハイディ トルシェイム，
ハイディ トルシェイム，
ピラダ スッパピパット，
ピラダ スッパピパット，
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
シンセティック ジェノミクス ヴァクシンズ， インコーポレーテッド
シンセティック ジェノミクス ヴァクシンズ， インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー, シンセティック ジェノミクス ヴァクシンズ， インコーポレーテッド, シンセティック ジェノミクス ヴァクシンズ， インコーポレーテッド filed Critical ノバルティス アーゲー
Publication of JP2016501020A publication Critical patent/JP2016501020A/ja
Publication of JP2016501020A5 publication Critical patent/JP2016501020A5/ja
Application granted granted Critical
Publication of JP6421128B2 publication Critical patent/JP6421128B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2015544499A 2012-12-03 2013-12-02 リアソータントインフルエンザａウイルス Active JP6421128B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261732809P 2012-12-03 2012-12-03
US61/732,809 2012-12-03
PCT/EP2013/075294 WO2014086732A2 (en) 2012-12-03 2013-12-02 Influenza virus reassortment

Publications (3)

Publication Number Publication Date
JP2016501020A JP2016501020A (ja) 2016-01-18
JP2016501020A5 JP2016501020A5 (https=) 2017-01-19
JP6421128B2 true JP6421128B2 (ja) 2018-11-07

Family

ID=49713076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015544499A Active JP6421128B2 (ja) 2012-12-03 2013-12-02 リアソータントインフルエンザａウイルス

Country Status (11)

Country Link
US (3) US9708585B2 (https=)
EP (1) EP2925356A2 (https=)
JP (1) JP6421128B2 (https=)
KR (1) KR20150110494A (https=)
CN (1) CN105120893B (https=)
AU (2) AU2013354219A1 (https=)
BR (1) BR112015012380A2 (https=)
CA (1) CA2893429A1 (https=)
HK (1) HK1214959A1 (https=)
MX (1) MX2015006927A (https=)
WO (1) WO2014086732A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150110494A (ko) * 2012-12-03 2015-10-02 노파르티스 아게 재배열 인플루엔자 a 바이러스
US10323231B2 (en) * 2015-04-24 2019-06-18 University Of Rochester Attenuated influenza vaccines and uses thereof
HK1254344A1 (zh) 2015-06-26 2019-07-19 Seqirus UK Limited 抗原匹配的流感疫苗
GB201602535D0 (en) * 2016-02-12 2016-03-30 Univ Edinburgh Improved flu vaccine yield
CN111032861B (zh) * 2017-08-28 2023-09-12 一般财团法人阪大微生物病研究会 重配流感病毒的阶段性制备方法
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
CN111315407B (zh) * 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
KR101954904B1 (ko) 2018-10-15 2019-03-06 남종규 복층의 태양광 설치 구조
CN111647610B (zh) * 2020-06-02 2021-09-03 扬州大学 一种互换ha和ns1缺失基因包装信号的h9n2亚型禽流感病毒及其构建方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
ATE384126T1 (de) 1998-06-12 2008-02-15 Sinai School Medicine Interferon induzierende genetisch veränderte attenuierte viren
TR200200776T2 (tr) 1999-09-24 2002-06-21 Smithkline Beecham Biologicals S.A. Burun içi grip virüsü aşısı.
JP4698112B2 (ja) 2000-03-03 2011-06-08 一般財団法人化学及血清療法研究所 無血清培養かつ浮遊培養可能な細胞及び当該細胞を用いたワクチン用ウイルスの製造法
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
JP2004536785A (ja) 2001-02-23 2004-12-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規なワクチン
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
AU2005230708B2 (en) 2004-04-05 2009-01-15 Zoetis Services Llc Microfluidized oil-in-water emulsions and vaccine compositions
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
NZ551640A (en) 2004-05-20 2010-05-28 Id Biomedical Corp Process for the production of an influenza vaccine
ATE547511T1 (de) 2004-12-23 2012-03-15 Medimmune Llc Nichttumorbildende mdck-zellinie zur vermehrung von viren
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
RU2008101367A (ru) 2005-06-21 2009-08-10 Медиммун, Ллк (Us) Способы и композиции для экспрессии отрицательной смысловой вирусной рнк в собачьих клетках
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
CA2627971A1 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg. Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
WO2007052061A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
WO2007126810A2 (en) * 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
PT2016194E (pt) 2006-04-19 2015-07-20 Medimmune Llc Métodos e composições para expressar arn viral de polaridade negativa em células caninas
KR101151202B1 (ko) 2006-10-12 2012-06-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 수중유 에멀젼 애주번트를 포함하는 백신
SG177141A1 (en) 2006-12-06 2012-01-30 Novartis Ag Vaccines including antigen from four strains of influenza virus
WO2008157419A2 (en) * 2007-06-13 2008-12-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides of influenza virus
EP2045323A1 (en) 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
JP5686741B2 (ja) * 2008-12-16 2015-03-18 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ インフルエンザワクチンの生成
EP2233152A1 (en) 2009-03-24 2010-09-29 Avir Green Hills Biotechnology Research Development Trade Ag High growth reassortant influenza A virus
EP2573184A1 (en) 2009-05-21 2013-03-27 Novartis AG Reverse genetics using non-endogenous POL I promoters
SG176178A1 (en) * 2009-06-25 2011-12-29 Medimmune Llc Swine influenza hemagglutinin variants
WO2011012999A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
AU2011254204B2 (en) * 2010-05-21 2015-08-20 Seqirus UK Limited Influenza virus reassortment method
FR2962739B1 (fr) * 2010-07-13 2014-01-31 Univ Claude Bernard Lyon Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza
KR20150110494A (ko) * 2012-12-03 2015-10-02 노파르티스 아게 재배열 인플루엔자 a 바이러스

Also Published As

Publication number Publication date
US10500266B2 (en) 2019-12-10
BR112015012380A2 (pt) 2017-09-12
EP2925356A2 (en) 2015-10-07
HK1214959A1 (zh) 2016-08-12
CN105120893B (zh) 2018-11-13
US9708585B2 (en) 2017-07-18
AU2018232956B2 (en) 2020-10-01
MX2015006927A (es) 2016-02-05
WO2014086732A2 (en) 2014-06-12
AU2013354219A1 (en) 2015-07-02
AU2018232956A1 (en) 2018-10-11
CN105120893A (zh) 2015-12-02
US20170326227A1 (en) 2017-11-16
US20200155666A1 (en) 2020-05-21
US20150315548A1 (en) 2015-11-05
WO2014086732A3 (en) 2014-07-24
CA2893429A1 (en) 2014-06-12
JP2016501020A (ja) 2016-01-18
KR20150110494A (ko) 2015-10-02
WO2014086732A8 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
JP6279503B2 (ja) インフルエンザウイルスの再集合
JP6082483B2 (ja) インフルエンザウイルス再集合方法
JP6525469B2 (ja) インフルエンザｂ型ウイルス再集合
JP6421128B2 (ja) リアソータントインフルエンザａウイルス
JP2016521553A (ja) インフルエンザウイルス再集合
JP5836266B2 (ja) 非内因性ｐｏｌＩプロモーターを使用した逆遺伝学
JP2011522874A (ja) 季節性および汎流行性の防御のための混合インフルエンザワクチン
JP2016104004A (ja) ウイルスレスキューのための改善された逆遺伝学
JP2016506724A (ja) インフルエンザウイルスの再集合
JP2012517416A (ja) 増加した量のｈ３抗原を含むインフルエンザワクチン
AU2014203051B2 (en) Influenza Virus Reassortment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180731

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180921

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181015

R150 Certificate of patent or registration of utility model

Ref document number: 6421128

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250